25 Nov

Proposed issue of securities - ACW

Proposed issue of securities Proposed issue of securities 1 / 11 Announcement Summary Entity name ACTINOGEN MEDICAL LIMITED Announcement Type New announcement Date of this announcement 25/11/2021 The Proposed issue is: Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan ASX +security code +Security description Maximum Number of +securities to be issued ACW ORDINARY FULLY PAID 37,037,037 +Record date 24/11/2021 Offer closing date 13/12/2021 +Issue date 20/12/2021 Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +securities to be issued ACW ORDINARY FULLY PAID 88,888,889 Proposed +issue date 31/1/2022 Refer to next page for full details of the announcement A placement or other type of issue A placement or other type of issue An offer of securities under a securities purchase plan Proposed issue of securities Proposed issue of securities 2 / 11 Part 1 - Entity and announcement details 1.1 Name of +Entity ACTINOGEN MEDICAL LIMITED We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules. If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation). 1.2 Registered Number Type ABN Registration Number 14086778476 1.3 ASX issuer code ACW 1.4 The announcement is 1.5 Date of this announcement 25/11/2021 1.6 The Proposed issue is: A placement or other type of issue A placement or other type of issue An offer of +securities under a +securities purchase plan New announcement Proposed issue of securities Proposed issue of securities 3 / 11 Part 4 - Details of proposed offer under securities purchase plan Part 4A - Conditions 4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities under the +securities purchase plan issue can proceed on an unconditional basis? No Proposed issue of securities Proposed issue of securities 4 / 11 Part 4B - Offer details Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued ASX +security code and description ACW : ORDINARY FULLY PAID Will the proposed issue of this +security include an offer of attaching +securities? Details of +securities proposed to be issued ASX +security code and description ACW : ORDINARY FULLY PAID Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted 37,037,037 Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)? Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)? Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)? Is the minimum acceptance unit based or dollar based? Please enter the minimum acceptance value $ 2,500 Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)? Is the maximum acceptance unit based or dollar based? Please enter the maximum acceptance value $ 30,000 Dollar based ($) Yes Dollar based ($) Yes No No No Dollar based ($) Yes Dollar based ($) Yes No No No Dollar based ($) Yes Dollar based ($) Yes No No No Proposed issue of securities Proposed issue of securities 5 / 11 Describe all the applicable parcels available for this offer in number of securities or dollar value $2,500, $5,000, $10,000, $20,000, $30,000 Offer price details Has the offer price been determined? In what currency will the offer be made? AUD - Australian Dollar What is the offer price per +security? AUD 0.13500 Oversubscription & Scale back details Will a scale back be applied if the offer is over-subscribed? Describe the scale back arrangements The Company reserves the right to scale back applications under the SPP at its absolute discretion. Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Part 4C - Timetable 4C.1 Date of announcement of +security purchase plan 25/11/2021 4C.2 +Record date 24/11/2021 4C.3 Date on which offer documents will be made available to investors 29/11/2021 4C.4 Offer open date 29/11/2021 4C.5 Offer closing date 13/12/2021 4C.7 +Issue date and last day for entity to announce results of +security purchase plan offer 20/12/2021 Yes Yes Yes Yes Yes Yes Yes Yes Yes Proposed issue of securities Proposed issue of securities 6 / 11 Part 4D - Listing Rule requirements 4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements? Part 4E - Fees and expenses 4E.1 Will there be a lead manager or broker to the proposed offer? 4E.1a Who is the lead manager/broker? Bell Potter Securities Limited 4E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker? Management fee of 3% of proceeds of the SPP. 4E.2 Is the proposed offer to be underwritten? 4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission? 4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer N/A Part 4F - Further Information 4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue Proceeds towards an expanded Fragile X program to North America; depression associated with cognitive impairment (3rd disease indication); early assessment of Alzheimer¿s Disease biomarker data; additional GMP manufacturing ,Offer costs & working capital. 4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful? 4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer Hong Kong, Indonesia, Isle of Man, Singapore, Switzerland, United Kingdom No No No Yes Yes Proposed issue of securities Proposed issue of securities 7 / 11 4F.3 URL on the entity's website where investors can download information about the proposed offer https://actinogen.com.au/investor-centre/#Share-Purchase-Plan 4F.4 Any other information the entity wishes to provide about the proposed offer N/A Proposed issue of securities Proposed issue of securities 8 / 11 Part 7 - Details of proposed placement or other issue Part 7A - Conditions 7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis? Part 7B - Issue details Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Will the proposed issue of this +security include an offer of attaching +securities? Details of +securities proposed to be issued ASX +security code and description ACW : ORDINARY FULLY PAID Number of +securities proposed to be issued 88,091,667 Offer price details Are the +securities proposed to be issued being issued for a cash consideration? In what currency is the cash consideration being paid? AUD - Australian Dollar What is the issue price per +security? AUD 0.13500 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Yes Yes No Existing class No Proposed issue of securities Proposed issue of securities 9 / 11 Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Will the proposed issue of this +security include an offer of attaching +securities? Details of +securities proposed to be issued ASX +security code and description ACW : ORDINARY FULLY PAID Number of +securities proposed to be issued 797,222 Offer price details Are the +securities proposed to be issued being issued for a cash consideration? In what currency is the cash consideration being paid? AUD - Australian Dollar What is the issue price per +security? AUD 0.13500 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Part 7C - Timetable 7C.1 Proposed +issue date 31/1/2022 Part 7D - Listing Rule requirements 7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? 7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? No Yes Yes No Existing class Proposed issue of securities Proposed issue of securities 10 / 11 placement capacity under listing rule 7.1? 7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? 7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? 7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? 7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? Part 7E - Fees and expenses 7E.1 Will there be a lead manager or broker to the proposed issue? 7E.1a Who is the lead manager/broker? Bell Potter Securities Limited 7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker? Management fee of 3% of proceeds and a placement selling fee of 3% of the placement proceeds (excluding any placement proceeds subscribed by any of the top 10 current shareholders). 7E.2 Is the proposed issue to be underwritten? 7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue N/A Part 7F - Further Information 7F.01 The purpose(s) for which the entity is issuing the securities Proceeds towards an expanded Fragile X program to North America; depression associated with cognitive impairment (3rd disease indication); early assessment of Alzheimer¿s Disease biomarker data; additional GMP manufacturing ,Offer costs & working capital. 7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? 7F.2 Any other information the entity wishes to provide about the proposed issue No No Yes No No Yes No No Proposed issue of securities Proposed issue of securities 11 / 11 7F.2 Any other information the entity wishes to provide about the proposed issue N/A 7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Actinogen Medical Limited (ASX:ACW) when you join Listcorp.